Secretome Therapeutics
Latest round
- Series A
Last raised
- May 2026
Total raised
- $30M
Investors
- 1
About Secretome Therapeutics
Secretome Therapeutics focuses on creating therapies from neonatal cardiac progenitor cells, emphasizing treatments for heart failure and dilated cardiomyopathy.4 mn on November 25, 2024.Secretome Therapeutics specializes in developing innovative therapies derived from neonatal cardiac progenitor cells (nCPCs) to address significant unmet medical needs in the treatment of cardiovascular diseases. Their lead products, STM-01 and its secretome, STM-21, target heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM).Secretome Therapeutics generates revenue primarily through the development and commercialization of investigational medicines via clinical trials and partnerships with healthcare organizations. Collaborations with clinical research institutions enable the assessment of product efficacy and safety. Specific pricing plans for their therapies have not been disclosed, but the company focuses on B2B relationships with research entities and healthcare providers, with potential revenue streams from successful trial outcomes leading to licensing agreements or partnerships for STM-01 and STM-21.
Who invested in Secretome Therapeutics
1 investor across 1 round
See all investors in Secretome Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 27, 2026
Amount
$30M
Investors
Questions about Secretome Therapeutics
Who invested in Secretome Therapeutics?
Secretome Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Secretome Therapeutics raised?
Secretome Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Secretome Therapeutics last raise money?
Secretome Therapeutics's most recent round on record is a Series A, in May 2026.
What does Secretome Therapeutics do?
Secretome Therapeutics focuses on creating therapies from neonatal cardiac progenitor cells, emphasizing treatments for heart failure and dilated cardiomyopathy.
Where is Secretome Therapeutics headquartered?
Secretome Therapeutics is headquartered in Baltimore, US.
Which VCs invest in companies like Secretome Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Secretome Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Secretome Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.